Different sequencing-service levels and accessory services are offered, and are tailored to meet different sequencing requirements. High-quality results have an accuracy of >99% for single reads and >99.99% for verification and de novo publication-ready sequences. Template purification is optional, and is performed using Wizard® PCR Preps DNA Purification System (Promega), Montage™ PCR96 Cleanup Kit (Millipore) or GENECLEAN® II Kit (Qbiogene). Plasmids (including large constructs, such as PACs, and BACs), cosmids, M13 phages, PCR fragments, and genomic DNA can be used as templates or project starting material.

Single-read sequencing (short read up to 500 bases) is ideal for analysis of cDNAs and ESTs, identification of clones, and verification of vector/insert transitions. Project turnaround times are fast, e.g., 3~5 working days for preparation and sequencing of small order volumes.

Verification sequencing provides confirmation of an already-known DNA sequence, as well as detection of mutations or deletions. Both DNA strands are completely sequenced using the appropriate strategy and custom primers based on the provided DNA sequence. The sequence is verified against a provided reference sequence.

De novo publication-ready sequencing is for de novo sequence determination. Results are suitable for publication. Both DNA strands are completely sequenced, and the sequence is fully edited and assembled.

Specialty sequencing is for sequencing of large plasmids (e.g., BACs, cosmids), or sequencing of genomic DNA, and can include mapping and screening of libraries, end sequencing, internal sequencing, or full-length sequencing.

Large-scale sequencing (e.g., whole-genome and EST) including the production of BAC or shotgun-cloned libraries is also available. For large-scale projects, a dedicated project management plan and project team is implemented to carry out all necessary work in due speed and to the highest accuracy and quality levels.

Additional services, such as library construction, PCR amplification, and primer design and synthesis can also be performed.

Shanghai Biochip Co., Ltd.（SBC） was founded in Aug. 2001. The existing shareholders of the company include some well-known universities, research institutes, hospitals and enterprises in China. In Feb. 2003, the National Development and Reform Commission authorized SBC to build up and operate the National Engineering Center for biochip at Shanghai project. The company is located in the Zhangjiang High-tech Park Biotech&Pharmaceutical Industrial Base in Pudong Shanghai with a total area of 40,000 square meters, a construction area of over 20,000 square meters, and a current employee number of more than 300 people.

In accordance with company's development strategy and the construction requirements raised by National Development and Reform Commission for the National Engineering Center, SBC is committed to applying and promoting biotechnology development and products for life science research、health-care、 drug discovery and other fields. Through more than 10 years of construction and development, the technology innovation service system is established which is based on the core platforms of the biological sample bank, tissue chips, gene expression chips and the next-generation sequencing; The industrialized system which takes molecular medical diagnosis technology and product development as the core competitiveness has been set up; And three main business areas which include the services for research and drugs R&D, molecular medicine inspection services, and production and sales of molecular diagnostic product.

SBC obeys the value idea of “Scientific innovation, Business orientation, Career development”, follows the construction requirements for the National Engineering Center, and strives to make the company an internationally-advanced national bio-chip industrialization base which integrates the function of technology innovation, achievements transformation, comprehensive service and personal training as a whole. What’s more, the company’s strategic goal is to be an innovative benchmark enterprise among the industry with an level internationally-advanced and has the capability of independent research and development. It would make a contribution to the goal of making Shanghai an influential technology innovation center and also contribute to the domestic field of biomedical science and technology innovation and industrialization in our country.